The role of echocardiography in the non-invasive diagnosis of cardiac amyloidosis

被引:31
作者
Cacciapuoti F. [1 ]
机构
[1] Department of Internal Medicine and Geriatry, Second University of Naples, Piazza L. Miraglia 2, Naples
关键词
2-D echocardiography; Cardiac amyloidosis; Endomyocardial biopsy; Integrated backscatter; New echocardiographic techniques;
D O I
10.1007/s12574-015-0249-1
中图分类号
学科分类号
摘要
Introduction: The diagnosis of cardiac amyloidosis (CA) is usually performed by endomyocardial biopsy; however, possible sampling errors and procedural risks such as cardiac tamponade, malignant arrhythmias and bleeding risk, limit its use. Therefore, a non-invasive diagnostic method appears to be necessary. Materials and methods: Echocardiography plays an important role in this need. Conventional two-dimensional echocardiography appears able to detect some specific and distinguishing signs of cardiac amyloid infiltration. Results and conclusions: Of these, thickened right and left ventricular (LV) myocardium, normal or small LV cavity size in contrast to enlarged biatrial cavities, diffuse hyper-refractile ‘granular sparkling’ appearance and ‘mismatch’ ECG/ECHO are the most specific findings. The magnitude of cyclic variation recorded with integrated backscatter reflects structural changes in the myocardium. In patients with CA, this magnitude is reduced because myocardial amyloid infiltration is characterized by a reduction of number of “contractile” fibers. Other informations concerning LV dysfunction CA-related can be obtained by Tei index. Finally, new echocardiographic imaging modalities, such as tissue Doppler, Doppler-based strain, speckle tracking imaging and three-dimensional echocardiography, can provide some findings regarding the preclinical stages of LV dysfunction when other echocardiographic measurements are showing normal; however, these are unable to provide a non-invasive diagnosis of cardiac amyloidosis. © 2015, Japanese Society of Echocardiography.
引用
收藏
页码:84 / 89
页数:5
相关论文
共 31 条
[1]  
Falk R.H., Comenzo R.I., Skinner M., The systemic amyloidoses, New Engl J Med, 337, pp. 898-909, (1997)
[2]  
Khan M.F., Falk R.H., Amyloidosis, Postgrad Med, 77, pp. 686-693, (2001)
[3]  
Gertz M.A., Lacy M.Q., Dispenzieri A., Amyloidosis, Hematol Oncol Clin North Am, 13, pp. 1211-1233, (1999)
[4]  
Shah K., Inoue Y., Mehra M., Amyloidosis of the heart: a comprehensive review, Arch Intern Med, 166, pp. 1805-1813, (2006)
[5]  
Falk R.H., Diagnosis and management of the cardiac amylodoses, Circulation, 112, pp. 2047-2060, (2005)
[6]  
Klein A.L., Hatle L.K., Burstow D.J., Et al., Doppler characterization of left ventricular diastolic function in cardiac amyloidosis, J Am Coll Cardiol, 13, pp. 1017-1026, (1989)
[7]  
Dubrey S.W., Cha K., Anderson J., Et al., The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement, QJM, 91, pp. 141-157, (1998)
[8]  
Hattori T., Takei Y., Koyama J., Et al., Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy, Amyloid, 10, pp. 229-239, (2003)
[9]  
Merlini G., Westermark P., The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies, J Intern Med, 225, pp. 159-178, (2004)
[10]  
Dubrey S.W., Cha K., Simms R.W., Et al., Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis, Am J Cardiol, 77, pp. 313-315, (1996)